ADRX-0134

ADRX-0134 is a preclinical antibody-drug conjugate (ADC) developed by Adcentrx Therapeutics. It targets NaPi2b, a sodium-dependent phosphate transporter (SLC34A2) that is highly expressed on the surface of lung and ovarian cancer cells but has minimal expression in normal tissues. The ADC consists of a human IgG1 antibody conjugated at drug-antibody ratio 8 (DAR8) with AP052, a clinically validated microtubule inhibitor payload also used in Adcentrx's lead program. This design aims to expand the therapeutic window compared to existing auristatin-based ADCs such as vedotin technology. Preclinical studies have shown strong efficacy in lung and ovarian tumor models, with favorable pharmacokinetics and safety profiles[1][3][4]. ADRX-0134 offers a differentiated approach for patients with lung and ovarian cancers where few viable treatment options exist[1][2].